Edimer Pharmaceuticals edimerpharma.com


Public list: Smart Money VCs (6328) Pharma Startups (4733) Rare Diseases (131)

Edimer Pharmaceuticals is dedicated to developing EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED). XLHED is a rare orphan disease that causes a range of symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. EDI200 has been shown to bind specifically to the EDA-A1 receptor, activating the signaling pathways that lead to normal development.

Edimer Pharmaceuticals is dedicated to developing EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED). XLHED is a rare orphan disease that causes a range of symptoms including lack of sweat glands, poor temperature control, r...Show all

Company (Alive / Active)

Phone: 617-758-4300

Fax:

55 Cambridge Parkway
Suite 102W
Cambridge, 02142
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Edimer Pharmaceuticals $18M Jul 30, 2013

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Edimer Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 5 investors
There is no Competitors data available for this company. Please select another tab.